Efficacy of biologics and oral small molecules for atopic dermatitis: a systematic review and meta-analysis

References

• Megna M, Napolitano M, Patruno C, et al. Systemic treatment of adult atopic dermatitis: a review. Dermatol Ther. 2017;7(1):1–23.
   PubMed Web of Science ®Google Scholar
• Baghoomian W, Na C, Simpson EL. New and emerging biologics for atopic dermatitis. Am J Clin Dermatol. 2020;21(4):457–465.
   PubMed Web of Science ®Google Scholar
• Nusbaum KB, Nguyen CM, Fleischer AB. Emerging systemic therapies for atopic dermatitis: biologics. J Dermatolog Treat. 2020;1–5.
   PubMed Web of Science ®Google Scholar
• Ahn J, Choi Y, Simpson EL. Therapeutic new era for atopic dermatitis: part 1. biologics. Ann Dermatol. 2021;33(1):1–10.
   PubMed Web of Science ®Google Scholar
• Ahn J, Choi Y, Simpson EL. Therapeutic new era for atopic dermatitis: part 2. Small molecules. Ann Dermatol. 2021;33(2):101–107.
   PubMed Web of Science ®Google Scholar
• Nusbaum KB, Nguyen CM, Fleischer AB. Jr. Emerging systemic therapies for atopic dermatitis: oral small molecules and targeted topical agents. J Dermatolog Treat. 2020;3:1–5.
   Google Scholar
• Thomas KS, Apfelbacher CA, Chalmers JR, et al. Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting. Br J Dermatol. 2021;185(1):139–146.
   PubMed Web of Science ®Google Scholar
• Schmitt J, Spuls PI, Thomas KS, et al. The harmonising outcome measures for eczema (HOME) statement to assess clinical signs of atopic eczema in trials. J Allergy Clin Immunol. 2014;134(4):800–807.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions. Hoboken (NJ): John Wiley & Sons; 2019.
   Google Scholar
• Yosipovitch G, Reaney M, Mastey V, et al. Peak pruritus numerical rating scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol. 2019;181(4):761–769.
   PubMed Web of Science ®Google Scholar
• Boutron I, Page MJ, Higgins JPT, et al. Chapter 7: considering bias and conflicts of interest among the included studies. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane handbook for systematic reviews of interventions version 6.2. London: Cochrane; 2021.
   Google Scholar
• Higgins JSJ, Page MJ, Elbers RG, et al. Chapter 8: assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane handbook for systematic reviews of interventions version 6.2. London: Cochrane; 2021.
   Google Scholar
• Deeks JJHJ, Altman DG. Chapter 10: analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane handbook for systematic reviews of interventions version 6.2. London: Cochrane; 2021.
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, The PRISMA Group, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Med. 2009;6(7):e1000097.
   PubMed Web of Science ®Google Scholar
• Simpson E, Sinclair R, Forman S, et al., editors. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: results from the phase 3 JADE MONO-1 study. Poster session presented at: European Academy of Dermatology and Venereology 28th Congress; 2019, Oct 9–13; Madrid, Spain.
   Google Scholar
• Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical Trial. JAMA Dermatol. 2020;156(8):863–873.
   PubMed Web of Science ®Google Scholar
• Gooderham MJ, Forman SB, Bissonnette R, et al. Efficacy and safety of oral janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol. 2019;155(12):1371–1379.
   PubMed Web of Science ®Google Scholar
• Bieber T, Simpson EL, Silverberg JI, et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med. 2021;384(12):1101–1112.
   PubMed Web of Science ®Google Scholar
• Simpson E, Lacour JP, Spelman L, et al. Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183(2):242–255.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Forman S, Silverberg JI, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis: results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5). J Am Acad Dermatol. 2021;85:62–70.
   PubMed Web of Science ®Google Scholar
• Reich K, Kabashima K, Peris K, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(12):1333–1343.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Silverberg JI, Nemoto O, et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol. 2019;80(4):913–921.
   PubMed Web of Science ®Google Scholar
• AbbVie News Center [Internet]. Chicago (IL): AbbVie Inc. RINVOQ™ (upadacitinib) monotherapy shows improvement in skin clearance and itch in first phase 3 study for atopic dermatitis; 2020 Jun 18 [cited 2021 Mar 26]. Available from: https://news.abbvie.com/news/press-releases/rinvoq-upadacitinib-monotherapy-shows-improvement-in-skin-clearance-and-itch-in-first-phase-3-study-for-atopic-dermatitis.htm
   Google Scholar
• Guttman-Yassky EAJA, et al. editors. Primary results from a phase 2b, randomized, placebo-controlled trial of upadacitinib for  patients with atopic dermatitis. American Academy of Dermatology Annual Meeting; 2018, Feb 16–20; San Diego (CA).
   Google Scholar
• Kabashima K, Matsumura T, Komazaki H, et al. Trial of nemolizumab and topical agents for atopic dermatitis with pruritus. N Engl J Med. 2020;383(2):141–150.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Pinter A, Pulka G, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol. 2020;145(1):173–182.
   PubMed Web of Science ®Google Scholar
• Ruzicka T, Hanifin JM, Furue M, et al. Anti–interleukin-31 receptor a antibody for atopic dermatitis. N Engl J Med. 2017;376(9):826–835.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2. Br J Dermatol. 2021;184(3):437–449.
   PubMed Web of Science ®Google Scholar
• Silverberg J, Toth D, Bieber T, et al. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol. 2021;184(3):450–463.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Howell MD, Guttman-Yassky E, et al. Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J Allergy Clin Immunol. 2019;143(1):135–141.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Blauvelt A, Eichenfield LF, et al. Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial. JAMA Dermatol. 2020;156(4):411–420.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Flohr C, Eichenfield LF, et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol. 2018;78(5):863–871.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287–2303.
   PubMed Web of Science ®Google Scholar
• de Bruin-Weller M, Thaçi D, Smith C, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin a or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ.). Br J Dermatol. 2018;178(5):1083–1101.
   PubMed Web of Science ®Google Scholar
• Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130–139.
   PubMed Web of Science ®Google Scholar
• Thaçi D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016;387(10013):40–52.
   PubMed Web of Science ®Google Scholar
• Schmitt J, Spuls P, Boers M, et al. Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting. Allergy. 2012;67(9):1111–1117.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340–347.
   PubMed Web of Science ®Google Scholar